Familial Pompe Disease.

Med Arch

Neurology department, Faculty of medicine, Inonu University, Malatya, Turkey.

Published: October 2015

Introduction: Pompe disorder is a rare glycogen storage disorder that is due to a deficiency of the lysosomal alpha glycosidase enzyme. The heart, skeletal muscle, liver and nervous system can be affected from the lysosomal glycogen accumulation. Symptoms such as muscle weakness, hypotony, myopathy and respiratory failure develop. The onset may be at the infantile, adolescent or adult period depending on the enzyme level. The CK level is high in almost all patients. The diagnosis is made with enzyme level measurement and genetic analysis.

Case Report: We present a family with Pompe disease consisting of the asymptomatic mother and two siblings who presented with muscle weakness and respiratory failure and who had been followed-up with a diagnosis of muscular dystrophy for a long time.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639334PMC
http://dx.doi.org/10.5455/medarh.2015.69.342-344DOI Listing

Publication Analysis

Top Keywords

pompe disease
8
muscle weakness
8
respiratory failure
8
enzyme level
8
familial pompe
4
disease introduction
4
introduction pompe
4
pompe disorder
4
disorder rare
4
rare glycogen
4

Similar Publications

Late-onset Pompe disease (LOPD) is a rare, autosomal recessive metabolic disorder that is heterogeneous in disease presentation and progression. People with LOPD report a significantly lower physical, psychological, and social quality of life (QoL) than the general population. This study investigated how individuals' self-reported LOPD status (improving, stable, declining) relates to their QoL.

View Article and Find Full Text PDF

Background: Pompe disease is a glycogen storage disease primarily affecting striated muscles. Despite its main manifestation in muscles, patients with Pompe disease may exhibit non-muscle symptoms, such as hearing loss, suggesting potential involvement of sensory organs or the nervous system due to glycogen accumulation.

Aims: This study aimed to evaluate the presence of concomitant small and large fiber neuropathy in patients with Pompe disease.

View Article and Find Full Text PDF

Advances in Disease-Modifying Therapeutics for Chronic Neuromuscular Disorders.

Semin Respir Crit Care Med

December 2024

Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, Ohio.

Neuromuscular disorders can cause respiratory impairment by affecting the muscle fibers, neuromuscular junction, or innervation of respiratory muscles, leading to significant morbidity and mortality. Over the past few years, new disease-modifying therapies have been developed and made available for treating different neuromuscular disorders. Some of these therapies have remarkable effectiveness, resulting in the prevention and reduction of respiratory complications.

View Article and Find Full Text PDF

For years, the treatment of many cardiomyopathies has been solely focused on symptom management. However, cardiomyopathies have a genetic substrate, and directing therapy towards the pathophysiology rather than the epiphenomenon of the disease may be a winning strategy. Gene therapy involves the insertion of genes or the modification of existing ones and their regulatory elements through strategies like gene replacement and gene editing.

View Article and Find Full Text PDF

Background: Lysosomal storage diseases (LSDs) can be treated with intravenous enzyme replacement therapy (ERT). ERT is being administered either in specialized clinics or in the home care setting. Studies indicate that home-based ERT can be considered safe and positively effects patient reported outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!